Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • ABTECT
  • Pipeline
    • Overview
    • Patients
    • Obefazimod for UC
    • Obefazimod for Crohn’s
    • Obefazimod for RA
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • General Meeting
  • Contact Us
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

La Gazette du Laboratoire

September 7, 2022

Abivax publie les résultats de l’étude de phase 2b d’obefazimod (ABX464) dans la rectocolite hémorragique

MedPage Today

September 7, 2022

First-in-Class Drug Brings Relief in Ulcerative Colitis

La Tribune Bourse

September 6, 2022

Abivax: une publication dans ‘The Lancet’ bien accueillie

The Pharma Letter

September 3, 2022

Abivax completes oversubscribed 49.2 million-euro cross-over financing

L'Usine Nouvelle

September 2, 2022

Abivax récolte plus de 49 millions d’euros pour avancer sur un traitement de la rectocolite hémorragique

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 46
© 2023 All rights reserved by ABIVAX | Website created by Stratégie et communication digitale : JLL CONSEIL Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Obefazimod for UC
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • General Meeting
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+